Long-Term Follow-Up on Systemic Bevacizumab Treatment in Recurrent Respiratory Papillomatosis.
Bevacizumab
anti-angiogenesis
malignant transformation
recurrent respiratory papillomatosis
Journal
The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
17
11
2020
received:
24
05
2020
accepted:
09
12
2020
pubmed:
1
1
2021
medline:
4
6
2021
entrez:
31
12
2020
Statut:
ppublish
Résumé
Recurrent respiratory papillomatosis (RRP) is a primarily benign disease affecting the entire respiratory tract. Treatment is challenging and usually involves surgical interventions and adjuvant medications. Previously, promising results on systemic administration of bevacizumab have been reported. However, experience on long-term systemic use in patients with RRP is not yet available. Here, we present our long-term follow-up on RRP patients undergoing systemic bevacizumab treatment. Case series. To describe experience on long-term systemic bevacizumab administration, we performed the underlying investigation. Clinical, radiological, and bronchoscopy data were collected. To date, a total of n = 5 patients has been treated with systemic bevacizumab at Muenster University Hospital. With a median follow-up since first systemic bevacizumab administration of 95.5 months long-term follow-up is illustrated. Following bevacizumab treatment partial remission or very good partial remission were achieved in all patients. After papilloma recurrence/progression due to bevacizumab discontinuation, further response was documented in all patients in whom bevacizumab was started again. In one patient, bevacizumab was discontinued due to loss of efficacy. Lung cancer developed in one patient with pulmonary papillomatosis prior to bevacizumab administration whereas three patients suffered from malignant transformation during bevacizumab treatment. Systemic bevacizumab led to long-term reduction in surgical interventions in all patients. Except from mild proteinuria and hypertension in two patients therapy was well tolerated. Systemic bevacizumab represents a promising long-term treatment option for aggressive forms of papillomatosis. Rate of malignant transformation under bevacizumab treatment, optimal treatment schedule, and influence on survival should be further evaluated in clinical trials. 4 Laryngoscope, 131:E1926-E1933, 2021.
Substances chimiques
Angiogenesis Inhibitors
0
Bevacizumab
2S9ZZM9Q9V
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
E1926-E1933Informations de copyright
© 2020 The Authors. The Laryngoscope published by Wiley Periodicals LLC. on behalf of The American Laryngological, Rhinological and Otological Society, Inc.
Références
Glikman D, Baroody FM. Images in clinical medicine. Recurrent respiratory papillomatosis with lung involvement. N Engl J Med 2005;352:e22.
Novakovic D, Cheng ATL, Zurynski Y, et al. A prospective study of the incidence of juvenile-onset recurrent respiratory papillomatosis after implementation of a national HPV vaccination program. J Infect Dis 2018;217:208-212.
Derkay CS, Bluher AE. Update on recurrent respiratory papillomatosis. Otolaryngol Clin North Am 2019;52:669-679.
Schraff S, Derkay CS, Burke B, Lawson L. American Society of Pediatric Otolaryngology members' experience with recurrent respiratory papillomatosis and the use of adjuvant therapy. Arch Otolaryngol Head Neck Surg 2004;130:1039-1042.
Rogers DJ, Ojha S, Maurer R, Hartnick CJ. Use of adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children. JAMA Otolaryngol Head Neck Surg 2013;139:496-501.
Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: a review. Laryngoscope 2008;118:1236-1247.
Healy GB, Gelber RD, Trowbridge AL, Grundfast KM, Ruben RJ, Price KN. Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial. N Engl J Med 1988;319:401-407.
Mohr M, Schliemann C, Biermann C, et al. Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis. Oncol Lett 2014;8:1912-1918.
Bedoya A, Glisinski K, Clarke J, Lind RN, Buckley CE, Shofer S. Systemic bevacizumab for recurrent respiratory papillomatosis: a single center experience of two cases. Am J Case Rep 2017;18:842-846.
Best SR, Mohr M, Zur KB. Systemic bevacizumab for recurrent respiratory papillomatosis: a national survey. Laryngoscope 2017;127:2225-2229.
Zur KB, Fox E. Bevacizumab chemotherapy for management of pulmonary and laryngotracheal papillomatosis in a child. Laryngoscope 2017;127:1538-1542.
Fernandez-Bussy S, Labarca G, Vial MR, et al. Recurrent respiratory papillomatosis and bevacizumab treatment. Am J Respir Crit Care Med 2018;197:539-541.
Cuestas G, Rodriguez V, Doormann F, Bellia Munzon P, Bellia Munzon G. Tracheobronchial and pulmonary papillomatosis without involvement of the larynx treated with intravenous bevacizumab in a child. Arch Argent Pediatr 2019;117:e72-e76.
Carnevale C, Ferran-De la Cierva L, Til-Perez G, et al. Safe use of systemic bevacizumab for respiratory recurrent papillomatosis in two children. Laryngoscope 2019;129:1001-1004.
Hamdi O, Dome J, Zalzal G, Preciado D. Systemic bevacizumab for end-stage juvenile recurrent respiratory papillomas: a case report. Int J Pediatr Otorhinolaryngol 2019;128:109706.
Silver RD, Rimell FL, Adams GL, Derkay CS, Hester R. Diagnosis and management of pulmonary metastasis from recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 2003;129:622-629.
Gates C, Tomboc P, Allison A, Carr M. Bevacizumab as adjuvant therapy for recurrent respiratory papillomatosis in an infant. Int J Pediatr Otorhinolaryngol 2019;129:109762.
Gelinas JF, Manoukian J, Cote A. Lung involvement in juvenile onset recurrent respiratory papillomatosis: a systematic review of the literature. Int J Pediatr Otorhinolaryngol 2008;72:433-452.
Best SR, Friedman AD, Landau-Zemer T, et al. Safety and dosing of bevacizumab (avastin) for the treatment of recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2012;121:587-593.
Sidell DR, Nassar M, Cotton RT, Zeitels SM, de Alarcon A. High-dose sublesional bevacizumab (avastin) for pediatric recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2014;123:214-221.